Neuroscientific appoints top doctor ahead of stem cell therapy rollout
The hire has come at a critical time as the company accelerates the development of its recently acquired StemSmart technology. StemSmart uses a specific type of stem cell, mesenchymal stromal stem cells (MSC), as a last-line infusion treatment for critically ill patients, including those experiencing severe immune complications from bone marrow transplants, kidney and lung transplant rejection and the inflammatory Crohn's disease.
The company expects later this year to receive the interim results from its latest compassionate trial involving patients with difficult-to-treat fistulising Crohn's disease, in which an open wound develops from a gut flare-up that extends out to the skin.
A successful trial will help the company validate its proprietary StemSmart technology in this patient group, who otherwise have limited treatment options.
Cole brings extensive experience to the table, having held clinical and academic leadership roles across Australia and overseas, including head of haematology and oncology at Perth Children's Hospital and professor of paediatric haematology and oncology at The University of Western Australia.
She is also director of stem cell transplantation at Perth Children's Hospital, placing her front and centre in Neuroscientific's race to employ stem cell therapy to treat some of the most debilitating transplant complications and autoimmune diseases.
The seasoned physician has additionally served on ethics committees and worked closely with national and international regulators, a skillset the company hopes will prove instrumental as it seeks regulatory approvals for StemSmart in Australia and abroad.
Commenting on her new role, Dr Cole said she was excited to help expand access to life-changing treatments, adding that the MSC therapy has been shown to modulate the immune system, reduce inflammation, promote immune tolerance and speed up tissue repair in some immune-related diseases.
She noted the clinical results so far for StemSmart in patients with immune-mediated disorders have been highly effective, and that the growing global momentum around stem cell therapies demonstrated that the sector's therapeutic potential could be invaluable.
'I look forward to helping expand access to life-changing therapy for patients affected by a range of immune and inflammatory disorders,' Cole said.
The MSCs used in StemSmart were pioneered over the past 20 years by Perth haematology medical scientist Dr Marian Sturm, NeuroScientific's incoming chief scientific officer, in her former role as facility director of Royal Perth Hospital's Cell and Tissue Therapies centre.
It offers a step up from traditional MSC manufacturing in that the cells are grown in a special media, becoming activated in the process. The platform technology was developed at Royal Perth Hospital (RPH) and manufactured using RPH's processes.
The cells have been used many times over the years via early phase clinical trials, studies and on compassionate grounds, with promising results.
If NeuroScientific's latest special access scheme (SAS) trial pans out, the company plans to escalate into phase 1/2 clinical trials as it sets its sights on obtaining the regulatory and funding approvals required for a full-scale rollout.
For now, all eyes are on the fistulising Crohn's data and the company's clinical and regulatory push. With Sturm and Cole holding its scientific and clinical reins, Neuroscientific can gear up to play in the big biotech league.
Is your ASX-listed company doing something interesting? Contact:
matt.birney@wanews.com.au
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sydney Morning Herald
an hour ago
- Sydney Morning Herald
Locksley nabs $5.3M to fuel US antimony-rare earths drilling blitz
The share price of Locksley Resources surged to 14.5 cents today on massive turnover - its highest price since 2022 - after the company turbocharged its United States critical minerals push by locking in a $5.3 million war chest. The oversubscribed capital raise, priced at 9.5c a share, drew a surge of institutional support led by heavyweight investor Tribeca Investment Partners. It was conducted under refreshed placement capacity approved at the company's recent shareholder meeting. Management says Tribeca's lead role as a cornerstone investor is a powerful endorsement of Locksley's US-facing strategy. The deal has also lured more than a dozen new institutions onto the register. The company will use the fresh capital to kick-start a high-impact drilling blitz at its Mojave antimony and rare earths grounds in California. Tucked deep in the Mojave Desert, Locksley's flagship project spans more than 250 claims across two standout zones dubbed the North Block and El Campo, which both scream potential. 'This funding places us in a strong position to execute our exploration and downstream plans across the Mojave project and unlock the full value of our US-based critical minerals portfolio.' Locksley Resources chairman Nathan Lude The North Block rubs shoulders with tenements held by US rare earths juggernaut MP Materials and hosts the historic Desert antimony mine, last worked in 1937. El Campo runs directly along strike of MP's fabled Mountain Pass rare earths mine and sits surrounded by MP's ground. Mountain Pass is America's only rare earths project and at the heart of America's supply chain overhaul. It first burst onto the scene in 1952 with an eye-popping 7 per cent total rare earths grade, which set the bar for decades.
The Age
an hour ago
- The Age
Locksley nabs $5.3M to fuel US antimony-rare earths drilling blitz
The share price of Locksley Resources surged to 14.5 cents today on massive turnover - its highest price since 2022 - after the company turbocharged its United States critical minerals push by locking in a $5.3 million war chest. The oversubscribed capital raise, priced at 9.5c a share, drew a surge of institutional support led by heavyweight investor Tribeca Investment Partners. It was conducted under refreshed placement capacity approved at the company's recent shareholder meeting. Management says Tribeca's lead role as a cornerstone investor is a powerful endorsement of Locksley's US-facing strategy. The deal has also lured more than a dozen new institutions onto the register. The company will use the fresh capital to kick-start a high-impact drilling blitz at its Mojave antimony and rare earths grounds in California. Tucked deep in the Mojave Desert, Locksley's flagship project spans more than 250 claims across two standout zones dubbed the North Block and El Campo, which both scream potential. 'This funding places us in a strong position to execute our exploration and downstream plans across the Mojave project and unlock the full value of our US-based critical minerals portfolio.' Locksley Resources chairman Nathan Lude The North Block rubs shoulders with tenements held by US rare earths juggernaut MP Materials and hosts the historic Desert antimony mine, last worked in 1937. El Campo runs directly along strike of MP's fabled Mountain Pass rare earths mine and sits surrounded by MP's ground. Mountain Pass is America's only rare earths project and at the heart of America's supply chain overhaul. It first burst onto the scene in 1952 with an eye-popping 7 per cent total rare earths grade, which set the bar for decades.
ABC News
2 hours ago
- ABC News
Australian doctor who volunteered in Gaza says hospital staff also starving
An anaesthetist at a public hospital in Perth says she decided to volunteer in Gaza after seeing images of the conflict in the media. "You just watch all these images on social media and television, and you just feel really helpless," Emma Giles said. After a 12-hour bus journey from Amman in Jordan, stopping at numerous checkpoints, Dr Giles arrived at Al-Quds Hospital in Gaza City in mid-May. She was only allowed to bring 3 kilograms of food with her and a limited amount of medical equipment for her four-week stay, where she lived at the hospital and worked with Palestinian medical staff. "There are fairly strict limits on what you can take with you," she told ABC Radio Perth's Jo Trilling. "You're allowed to take items which are for personal use only and for those that you can use in your own personal professional career. "So I couldn't take surgical stuff in, but I could take anaesthetic stuff in." Once at the hospital, Dr Giles got to work. "We had some anaesthetic machines which were quite similar to what I would use in Australia, but the disposable items weren't there," she said. "For example, [in Perth] I would put a breathing filter on my anaesthetic machine between every patient, so I don't transmit respiratory diseases, but we had none of those. Israel stopped allowing almost all food aid into Gaza on March 2. Dr Giles found the effect of severe food shortages was apparent in many of her patients by May. "We'd see a lot of people, particularly children, quite malnourished, poor healing," she said. "They would come back every two to three days to have further wash out of their really, really nasty wounds to try and prevent infection. "We'd just do it under anaesthesia." Dr Giles said the food shortages extended to the medical and nursing staff, who were only being given one meal a day by the hospital. "[The local staff] are absolutely exhausted and burnt out," she said. "They often work in multiple hospitals and do 24-hour shifts because travel is so difficult and dangerous. They choose to do longer shifts. Since she left, Dr Giles has been told the situation has worsened. "There is no food supplied by the hospital anymore," she said. "They're often starving and weak during the day, often feel a bit faint while they're working, and they're absolutely desperate to keep going." Dr Giles lost 6 kilograms during her four weeks in Gaza. On May 26, amid international outcry about the lack of food available, an organisation backed by the United States and Israel called the Gaza Humanitarian Foundation (GHF) began handing out food at distribution points. The Israeli military created long approach corridors for each of the GHF sites, and it soon became clear how dangerous they were. "The GHF started up close to where we were, about halfway through my time there, and that's when we started getting mass casualties as a real issue in the hospital," Dr Giles said. "They were open for maybe 10 to 15 minutes in a day, and then the people will just crowd in and get food. It's very much a survival of the fittest." The UN reported that as of July 21, 1,054 people had been killed in Gaza while trying to get food, 766 near GHF sites. "When they were crowding in [at GHF sites], often that would be seen as threatening by armed personnel around who would shoot them," Dr Giles said. "If we saw people walking past the hospital carrying bags of flour, we knew that there would be mass casualties coming in soon. "When you were operating on people, you often saw that the patients had this white ingrained flour in their hands — people who had actually managed to get food had then been wounded." Dr Giles travelled to Gaza as a volunteer with the Palestinian Australian New Zealand Medical Association (PANZMA).
